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Abstract.Three forms of lactoferrin (Lf) that differed in their levels of iron 
loading (Lf, LfFe, and LfFe2) were simultaneously labeled with the fluorophores 
AF350 and AF430. All three resulting fluorescent lactoferrins exhibited 
fluorescence resonance energy transfer (FRET), but they all presented different 
FRET patterns. Whereas only partial FRET was observed for Lf and LfFe, 
practically complete FRET was seen for the holo form (LfFe2). For each form of 
metal-loaded lactoferrin, the AF350–AF430 distance varied depending on the 
protein conformation, which in turn depended on the level of iron loading. Thus, 
the FRET patterns of these lactoferrins were found to correlate with their iron 
loading levels. In order to gain greater insight into the number of fluorophores 
and the different FRET patterns observed (i.e., their iron levels), a computational 
analysis was performed. The results highlighted a number of lysines that have the 
greatest influence on the FRET profile. Moreover, despite the lack of an X-ray 
structure for any LfFe species, our study also showed that this species presents 
modified subdomain organization of the N-lobe, which narrows its iron-binding 
site. Complete domain rearrangement occurs during the LfFe to LfFe2 transition. 
Finally, as an example of the possible applications of the results of this study, we 
made use of the FRET fingerprints of these fluorescent lactoferrins to monitor the 
interaction of lactoferrin with a healthy bacterium, namely Bifidobacterium breve. 
This latter study demonstrated that lactoferrin supplies iron to this bacterium, and 
suggested that this process occurs with no protein internalization. 
 









Lactoferrin is a glycoprotein (80 kDa) of the transferrin family with a high 
affinity for iron(III) [1, 2]. Lactoferrin possesses various biological functions, 
including antibacterial, antiviral, and antiparasitic activities [3]. High lactoferrin 
levels are found in colostrum and milk, and this protein is also present in most 
mucosal secretions, including uterine fluid, vaginal, and nasal secretions, as well 
as in tears [4, 5]. 
The extraordinary affinity of lactoferrin for iron undoubtedly determines part of 
its functionality. Indeed, lactoferrin is considered to form part of the innate 
immune system due to its effects on pathogen growth. Iron is essential for life and 
is a key nutrient for pathogenic microorganisms, which require this metal to 
survive and replicate. Life can to some extent be considered a battle for iron, so 
hosts must deprive undesirable guests of iron in order to combat the infections 
they cause. As a result, iron uptake by lactoferrin prevents the development of 
pathogenic microorganisms which cannot then access this metal. This is why blood 
lactoferrin levels increase markedly during infection. Indeed, lactoferrin 
concentrations increase in all biological fluids during most inflammatory 
reactions and viral infections, with the highest levels being detected at the nidus 
of the inflammation [6]. 
The clearest evidence that the immune function of lactoferrin is related to its iron 
affinity is the fact that whereas apolactoferrin (lactoferrin without iron) inhibits 
the growth of a large number of species of bacteria (such as Escherichia coli, some 
Pseudomonas, Yersinias, Listeria, Streptococcus, and Staphylococcus), 
hololactoferrin (iron-saturated lactoferrin) exhibits significantly lower inhibitory 
activities towards such bacteria [7–9]. The iron loading level of lactoferrin 
therefore partially determines its functionality. 
It should be noted that lactoferrin also has some effects on the immune system 
that have nothing to do with iron affinity. Thus, lactoferrin exerts antiviral effects 
by binding directly to DNA (or RNA) and by preventing the entry of viruses into 
cells, thereby stopping infections at an early stage [10–13]. 
Lactoferrin can also serve as an iron donor, supporting the growth of certain 





Lactobacilli, and Bifidobacteria coexist in an environment that is optimized for 
proliferation. 
X-ray diffraction studies, which are only available for the apo and holo forms of 
lactoferrin, have shown that it consists of one polypeptide chain containing 703 
amino acids, which forms two homologous globular domains named the N- and C-
lobes. The N-lobe corresponds to amino acid residues 1–333 and the C-lobe to 
residues 345–692, and the ends of these domains are connected by a short a-
helix (Fig. 1). These two homologous lobes are further subdivided into two similarly 
sized domains known as domain 1 and domain 2 (domains N1 and N2 in the N-lobe 
and domains C1 and C2 in the C-lobe), and the two iron-binding sites are located 
within the interdomain clefts of each lobe. In human lactoferrin, when two iron 
atoms are incorporated into the apoprotein, the C-lobe conformation does not 
change significantly whereas the N-lobe closes like a hinge to grip the metal. This 
results in different tertiary structures: iron-free apolactoferrin is characterized by 
an open conformation of the N-lobe and a closed conformation of the C-lobe, 
whereas both lobes are closed in the iron-rich hololactoferrin, as shown by X-ray. 
 
                  
 
Fig. 1 X-ray structures of Lf and LfFe2. Arrows indicate the conformational 
movement of the N-lobe when coordinating iron. The iron-binding sites are 





The chemical environments of the two iron(III) coordination sites are similar and 
consist of two phenolate oxygens from two tyrosine residues, one imidazole from 
a histidine residue, one carboxylate from an aspartate residue, and a synergistic 
adjacent bicarbonate or carbonate, which is stabilized by hydrogen bonding to the 
peptide chains that surround the active site. Despite this similarity, the two 
coordination sites of iron(III) can be distinguished kinetically and 
spectroscopically [18]. The three known forms of lactoferrin, namely 
apolactoferrin (Lf), the monoferric form (LfFe), and hololactoferrin (LfFe2) differ 
in their iron loading levels, which determine the functionality of the protein. 
The lysine residues on the external surface of lactoferrin can be used to 
covalently couple molecules [19–22] or clusters [23], permitting new 
functionality to be added to the protein. This option has been exploited for 
different applications, including increasing cell internalization levels, oral 
administration, rheology modulation, and for monitoring toxic non-transferrin 
bound iron. We use this functionalization to determine the iron loading level of 
the protein. The idea of incorporating a fluorescent moiety into lactoferrin is of 
considerable and widespread interest, especially in the field of biomedicine, as 
adequate functionalization could lead to fluorescence resonance energy transfer 
(FRET), an effect/process that is commonly used in sensors in biological 
research [24–26]. 
In the work described in the present paper, a pair of Alexa Fluor® (AF) 
fluorophores, AF350 and AF430, were chemically bound to Lf, LfFe, and LfFe2. As 
the emission band of the AF350 donor overlaps with the excitation band of the 
AF430 acceptor, simultaneous labeling of these lactoferrin species with both 
fluorophores (AF350 and AF430) offers the opportunity to achieve FRET, which is 
strongly dependent on the distance between the AF350 donor and the AF430 
acceptor. We show in this work that the FRET yield, which is the ratio of the 
emission intensities for the acceptor and donor, differs for Lf, LfFe, and LfFe2 
because the conformational changes that the protein undergoes during iron 
incorporation lead to variations in the donor–acceptor distance. As a result, the 
FRET pattern can be used as an indicator of the tertiary structure of lactoferrin, 
thus providing information on its iron load. Finally, we made use of this 





loading state of lactoferrin during its interaction with probiotic bacteria, a 
process which ends with the transfer of iron from the lactoferrin to the 
bacteria. 
Moreover, we performed a computational study to rationalize this dependency of 
the FRET pattern on the iron loading level. The reason that this study is 
interesting is that the evolution of the FRET pattern with the tertiary structure of 
the protein can be used to probe how, upon the uptake of the first iron(III) ion, the 
other lobe of the protein is prompted to take up the second iron(III) ion. No 
definitive answer is available to this question at present. 
 
Materials and methods 
Monoferric lactoferrin (LfFe) was purchased from Fonterra (Auckland, New 
Zealand; ref. no: 81665295/100). The apo and holo forms were prepared from this 
monoferric lactoferrin. 
Preparation of apolactoferrin (Lf) 
Lyophilized human milk LfFe (20 mg/mL) was totally desaturated of iron 
following successive dialysis steps against 0.1 M citric acid/citrate buffer (pH 
3.50) using a high retention seamless cellulose tubing membrane with a molecular 
weight cutoff (MWCO) of 12,000 Da. The citric acid/citrate buffer was changed 
several times until no characteristic iron lactoferrin absorbance at 464 nm (ε464 = 
2,500 M-1) was observed. The resulting colorless pale apolactoferrin solution was 
then dialyzed against phosphate buffer pH 6.80 and subsequently 
chromatographed (Sephadex G-25, GE Healthcare, Little Chalfont, UK). The 
concentration of apolactoferrin was measured by UV/vis spectroscopy based on 
the absorbance at 280 nm (ε280 = 92,300 M-1). 
Preparation of diferric lactoferrin (LfFe2) 
Based on a previously published procedure [27], 20 mg of lyophilized human milk 
LFe were dissolved in 1 mL of TRIS–Cl buffer pH 6.80 containing 5 mM sodium 
bicarbonate. This solution was then titrated with Fe citrate at 37 ºC under 
continuous stirring until the appearance of a characteristic dark reddish solution. 






Iron contents per lactoferrin were calculated directly by UV/vis spectroscopy from 
the relationship between the absorbance at 464 nm (ε464= 2,500 M-1) and that at 
280 nm (ε280 = 92,300 M-1). The iron/protein values obtained were 0 (Lf), 1.09 
(LfFe), and 1.97 (LfFe2). These values were obtained from triplicate preparations, 
with less than 8 % variation from the mean observed. The same lactoferrins 
were used for all subsequent experiments. This means that the iron content of 
every lactoferrin remained constant throughout the experiment. 
Preparation of fluorescent lactoferrins 
Lf, LfFe, or LfFe2 (2 mL, 20 mg/mL) was incubated in a buffered PBS solution at 
pH 8 with an excess of (a) AF350, (b) AF430, and finally (c) a mixture of the 
AF350 and AF430 fluorophore succinimidyl ester derivatives. The two former 
assays allowed the molar ratio required for the third reaction to be determined. 
Specifically, an AF350:AF430:protein molar ratio of 30:15:1 was used to prepare 
the samples. The labeling reactions were performed at room temperature under 
continuous stirring for 24 h. The resulting solutions were then exhaustively 
dialyzed at room temperature for 3 days against several changes of Milli-Q water 
(Millipore, Billerica, MA, USA) using a high retention seamless cellulose tubing 
membrane with a MWCO of 12,000 Da, and size exclusion chromatography 
(Sephadex G-25) was then performed to remove the unbound fluorophores. 
Protein-containing fractions were isolated. For apolactoferrin samples labeled 
with both fluorophores, the concentration of AF430 was directly calculated from 
the absorbance values of the UV–visible spectra at 430 nm (ε430 = 16,000 M-1) 
because the absorbances of apolactoferrin and AF350 are negligible at this 
wavelength. The concentration of AF350 was obtained from the absorbance at 
350 (ε350 = 19,000 M-1) by subtracting the absorbance of AF430 at this 
wavelength. The concentration of lactoferrin was obtained directly from the 
absorbance at 280 nm (ε280 = 92,300 M-1) because the absorbances of both 
fluorophores at this wavelength can be considered negligible. A similar procedure 
was performed to determine the number of fluorophores for LfFe and LfFe2, with 
the UV–visible spectrum of the starting lactoferrin subtracted from each labeled 
lactoferrin spectrum beforehand. The average number of fluorophores per 





very consistent (with less than 5 % variation from the mean) and were rounded 
to the nearest integer (Table 1). FRET yields from the three samples were also 
calculated, and standard deviations from the average were less than 3%. 
 
            
 
All UV–visible spectra were recorded with a Thermo Scientific (Waltham, MA, 
USA) Spectronic Unicam UV300 spectrophotometer, and all fluorescence spectra 
were recorded with a Varian (Palo Alto, CA, USA) Cary Eclipse fluorescence 
spectrophotometer. 
Incubation of AF-labeled lactoferrins with Bifidobacterium breve 
Human milk B. breve (10 mg/mL; Biosearch S.A., Granada, Spain; CECT7263) was 
incubated with LfFe2-AFs (4.86 x 10-6 M) under anaerobic conditions at 37 ºC in 
Hank’s solution for 1, 2, 3, and 6 h. Bacterial suspensions were then centrifuged at 
4,000 rpm and the supernatant solutions were analyzed using a Varian Cary 
Eclipse fluorescence spectrophotometer. No fluorescence was observed from the 
bacterial pellets. The iron concentrations of the supernatant solutions were 
measured by ICP, with values of >10-9 M obtained. Likewise, the protein 
concentrations in the supernatant solutions remained constant (in the range 4-5 
x 10-6 M, as measured by UV/vis spectroscopy based on the absorbance at 280 nm; 
ε280 = 92,300 M-1). 
Docking study 
Protein–ligand dockings were performed using the program GOLD 5.1. A harmonic 





(Lys301 or Lys296) and the C of the carboxylate group of the fluorophore. In the 
simulations where Lys301 or Lys296 were flexible, the Dunbrack rotamer library 
was used. The cavity was defined as a 20-Å sphere around Tyr82. 
Structural statistics 
The two scripts used in this work were written in Python and ported to the UCSF 
Chimera environment. Both can be obtained for free from the authors. 
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Figure SI1. Histogram of SAS values of the 46 Lys residues in Lf. Blue bars 
corresponds to values obtained for the Lf structure (pdb 1CB6), red bars to LfFe2 
structure (pdb 1N76) and yellow bars to the relative difference between iron free and 
iron loaded conformations.   
 
 
Figure SI2. Monitorization of FRET Fluorescence emission spectra for LfFe2-AFs 










Following a known procedure, apolactoferrin (Lf) and hololactoferrin (LfFe2) 
were prepared from the commercial monoferric form (LfFe). These three forms of 
lactoferrin with different iron loadings were treated with an excess of each AF 
fluorophore (or a mixture of both AF fluorophores) for 24 h and then 
exhaustively dialyzed until no fluorescence was detected in the dialysis reservoir. 
After isolating the protein-containing fractions, measurement of the UV–vis 
spectra allowed the final concentrations of each lactoferrin sample and the AF430 
and AF350 fluorophores to be calculated. These results yielded the average 
number of fluorophores per lactoferrin, as shown in Table 1. 
Our observations of the reactions of Lf, LfFe, and LfFe2 with AF350 and AF430 
allowed us to establish that the number of reaction sites does not depend on the 
type of fluorophore used, and that they should be reacted with the proteins to 
determine the stoichiometric ratio (see ‘‘Materials and methods’’). The 
fluorescence spectra of the solely AF350- and AF430-labeled lactoferrins showed 
emission bands centered at 445 and 540 nm upon excitation at 327 and 425 nm, 
respectively. As expected, the fluorescence properties of AF350 and AF430 were 
not significantly modified after covalent coupling to lactoferrin. 
AF350 and AF430 were chosen for use in this work due to the fact that the 
emission band of AF350 overlaps with the excitation band of AF430. Therefore, 
the simultaneous labeling of lactoferrin with both fluorophores (AF350 and 
AF430) is a good option for achieving FRET. The lactoferrins (Lf, LfFe, and LFe2) 
were finally incubated with an excess of a mixture of AF350 and AF430, using the 
same procedure as employed for the single AFs. The number of AF430 and AF350 
moieties in each labeled sample was calculated from the absorbances at 430 and 
350 nm in the UV–visible spectra (Fig. 2; see ‘‘Materials and methods’’). 
As shown in Table 1, incubation of the lactoferrins (Lf, LfFe, and LFe2) with an 
excess of a mixture of AF350 and AF430 yielded similar labeling results. The 
number of AF350 and AF430 molecules when the lactoferrins were labeled with a 
single fluorophore was six for Lf and five for both LfFe and LfFe2. Interestingly, the 
number of AF350 and AF430 molecules in the combined experiments was also 





LfFe-AFs, and five (3 AF350 + 2 AF430) for LfFe2-AFs. All of these results 
therefore indicate that the fluorophore-labeled apo form of lactoferrin has an 
extra fluorophore (either AF350 or AF430) than found in fluorophore-labeled 
LfFe and LfFe2. The three lactoferrins labeled with both AF350 and AF430 
exhibited FRET (Fig. 3). Excitation at 327 nm produced emission at 440 and 540 
nm. The FRET pattern and efficiency were found to be characteristic of every 




Fig. 2 UV–vis spectra of Lf-AFs indicating the number of AF350 and AF430 moities 
per protein in the combined AF350+AF430 labeling experiment. Concentrations of 
AF430, AF350, and protein were calculated from the absorbances at 430, 350, and 






In all cases, the emission at lower energy can be attributed to the AF430 acceptor 
and that at higher energy to the emission of the AF350 donor. In order to evaluate 
these different efficiencies, the %FRET value of each lactoferrin was calculated 
using the following equation, which normalizes the intensity of the emission of 
AF430 (IAF430) with respect to the intensity of the emission from both fluorophores 
(IAF350 + IAF430): 
      
 
Fig. 3 FRET fluorescence emission spectra of the Lf- AF350+AF430, LfFe-
AF350+AF430 and LfFe2-AF350+AF430 samples 
 
The calculated %FRET yield values obtained from the data shown in Fig. 3 imply 
that the efficiency of the energy transfer between both fluorophores varies. 





occur in Lf-AFs (%FRET = 50) or in LfFe-AFs (%FRET = 41), practically complete 
energy transfer occurs in LfFe2-AFs (%FRET = 91). Consequently, the FRET pattern 
represents a ‘‘fingerprint’’ of the particular fluorescent lactoferrin that produces it, 
and is related to the conformational changes that occur to the protein upon the 
incorporation of iron. 
Once these results had been analyzed, we aimed to correlate the energy transfer 
efficiency with the distance between the donor (AF350) and the acceptor (AF430), 
which obviously should be different in the three iron-loaded forms of Lf. 
In order to gain greater insight into the differences observed in the number of 
fluorophores and the FRET patterns observed among the distinct iron-loaded 
states of lactoferrin, a computational analysis was performed. Calculations were 
first employed to ascertain the location of the binding site of the extra AF430 that 
is present in Lf-3AF350+3AF430 as compared to LfFe- and LfFe2- 
3AF350+2AF430. Second, computation was used to identify the region (or regions) 
of the protein that influences the FRET efficiency. 
First, a comparative analysis of the solvent-accessible surface (SAS) for the 46 
lysines in the X-ray structures of Lf and LfFe2 was performed (see SI1 in the 
Electronic supplementary material, ESM). As has been reported previously, 
succinimidyl ester derivatives of AFs are excellent dyes for labeling proteins 
through reactions with the available lysines [29]. To identify the location of the 
additional AF430 in the apo-Lf form, we hypothesized that the sixth lysine (i.e., the 
one to which the additional AF430 binds) should show a dramatic decrease in 
solvent accessibility when the apo form converts to the holo form of lactoferrin (in 
other words, upon changing from Lf-AFs to between the donor (AF350) and the 
acceptor (AF430), which obviously should be different in the three iron-loaded 
forms of Lf. 
In order to gain greater insight into the differences observed in the number of 
fluorophores and the FRET patterns observed among the distinct iron-loaded 
states of lactoferrin, a computational analysis was performed. Calculations were 
first employed to ascertain the location of the binding site of the extra AF430 that 
is present in Lf-3AF350+3AF430 as compared to LfFe- and LfFe2-3AF350+2AF430. 





that influences the FRET efficiency. 
First, a comparative analysis of the solvent-accessible surface (SAS) for the 46 
lysines in the X-ray structures of Lf and LfFe2 was performed (see SI1 in the 
Electronic supplementary material, ESM). As has been reported previously, 
succinimidyl ester derivatives of AFs are excellent dyes for labeling proteins 
through reactions with the available lysines [29].  
        
Fig. 4 Locations of the four lysines whose solvent accessible surface (SAS) values 
decrease the most upon converting from the Lf to the LfFe2 form. The backbones are 
represented by ribbons. Regions colored green correspond to the C2 and N2 
subdomains, and those colored silver correspond to the C1 and N1 subdomains. The 
lysines of interest are represented as blue spheres at the Ne position and are labeled.  
 
To identify the location of the additional AF430 in the apo-Lf form, we 
hypothesized that the sixth lysine (i.e., the one to which the additional AF430 
binds) should show a dramatic decrease in solvent accessibility when the apo form 
converts to the holo form of lactoferrin (in other words, upon changing from Lf-
AFs to LfFe2-AFs). A program written in Python in house and implemented in the 





could not be done of the monoferric species since no X-ray structure of LfFe was 
available. 
Although most of the lysines were found to be highly exposed to the solvent, four 
residues (Lys282, Lys285, Lys296, and Lys301) presented a noticeable decrease 
in SAS during the conversion from Lf to LFe2. All of these residues are found in the 
N-lobe, and more specifically in the N1 region of the protein: Lys282 and Lys285 
are located at one of the external faces of the subdomain and Lys296 and Lys301 
at the entrance and core of the iron-binding site, respectively (Fig. 4). 
Significantly, Lys282, Lys285, and Lys296 exhibit large SAS values, thereby 
suggesting that interaction with a fluorophore should be independent of the 
protein conformation. In contrast, Lys301 exhibited a large SAS value in Lf but a 
value of almost zero in LFe2, meaning that this residue changes from being 
highly exposed in the apo form (Lf) to deeply buried in the holo one (LfFe2). 
To better ascertain whether Lys301 is the Lys to which AF430 binds, and to gain 
a better understanding of its molecular features, protein–ligand dockings of the 
fluorophore at this site were performed using the available crystal structures of Lf 
and LfFe2. As stated in the ‘‘Materials and methods’’ section, these calculations 
were undertaken using the program GOLD and the Chemscore scoring functions 
[30]. A restraint was added between N of the lysine and the carbon atom of the 
carbonyl group of the fluorophore during the run in order to achieve geometries 








   
Fig. 5 Lowest-energy solutions for the conformation of AF430 that are consistent 
with its binding to Lys301 in LfFe2 (left panel) and Lf (right panel). The fluorophores 
are represented as balls and sticks and the protein residues as sticks. The surfaces 
are also depicted in order to highlight the residues (red) that show the most steric 
hindrance with the fluorophore (blue) in LfFe2 
 
The predicted binding affinities for AF430 binding at Lys301 range from 18.8 to -
22.1 scoring units on going from Lf to LfFe2, respectively. For calculations 
performed with the Chemscore function, these values imply a predicted binding 
affinity that could reach the micromolar range for the former but that binding is 
impossible for the latter [31]. 
These findings were further confirmed by repeating the calculations with AF430 
on LfFe2, but adding greater flexibility to the Lys301 residue during docking (Fig. 
5). Although the predicted affinity of the best binding mode increased at 13.75 U, 
the binding affinity was still low and was substantially different to that obtained 
for Lf. Moreover, for the conjugation to occur, Lys301 must escape from a 
buried situation in LfFe2 (where it interacts strongly with a network of polar 
interactions with the carboxylic residues E216 and D297) to a conformation that 
is highly exposed to the solvent. Marked steric hindrance is observed for the 
environments of the iron-binding sites in the resulting geometry. These results 
confirm that conjugation of the dye at this position is only possible in the apo 
form of Lf. 





could be responsible for the change in FRET efficiency upon shifting from the 
apo-Lf to the holo-LfFe2 form. These calculations, which considered the variations 
in the distances between all lysine residues during the transition from Lf to LfFe2, 
were performed using an additional program written in house in Python and 
implemented in the UCSF Chimera package [32]. The script provided a 46 x 46 
matrix of the entire set of Lys–Lys distances. The comparative analysis of the X-ray 
structures of Lf and LfFe2 showed that most of the 46 Lys residues have inter-
residue distances that only rarely vary by >3 Å on average when the iron loading 
of the protein changes, thus remaining within the Fö rster distance range (Fig. 6). 
However, eight Lys residues, namely Lys99, 100, 113, 197, 200, 237, 241, and 
243, showed a different pattern, with variations of between 5 and 10 Å . Also, 
Lys180 showed variations that were slightly larger than 4 Å . 
 
                
 
Fig. 6 Bubble chart showing the average variations in inter-residue distances upon 
transitioning from Lf to LfFe2. The size of each circle is proportional to the 







                    
 
Fig. 7 Locations of the nine lysines whose average variations in inter-residue 
distance upon transitioning from Lf to LfFe2 exceed 4 Å . The backbones are 
represented as ribbons. Regions colored green correspond to the C2 and N2 
subdomains, and those colored silver correspond to the C1 and N1 subdomains. 
Putative lysines are represented as green spheres at the Ne position and are labeled 
 
Importantly, these eight residues were all found to be located in the N2 subregion 
of the N-lobe. This subregion makes the greatest contribution to the 
conformational transition from Lf to LfFe2 (Fig. 7). Lys301, which was previously 
identified as the binding site for the ‘‘extra’’   430, is located at the interface 
between the N1 and N2 subdomains. Both of these results suggest that, even upon 
shifting to the LfFe form of the metalloprotein, a conformational change occurs to 
the macromolecule consisting of a subdomain rearrangement of the N-lobe. 
Using our improved understanding of the relationship between the FRET profile 
and iron loading, the possibility of using fluorophore labeling to monitor iron 
loading in lactoferrin-dependent processes was investigated. In particular, we 
monitored the process by which lactoferrin can supply iron to a healthy 
bacterium, in this case B. breve. The bacteria were incubated with LfFe2-AFs for 
different durations (1–6 h) and the FRET patterns of the supernatant solutions 





supernatant solution exhibited a FRET pattern typical of the iron-free Lf-AFs form 
(Fig. 8). A negligible amount of iron was detected in this solution (concentration 
below 10-9 M), while the concentration of the protein (Lf) remained constant. 
This finding suggests that all of the iron initially bound to lactoferrin is released 
and incorporated into the bacteria after this time. Likewise, no fluorescence was 
observed from the centrifuged bacteria. Interestingly, we observed that the 
FRET pattern does not change gradually but sharply, in two steps: from LfFe2 to 
LfFe, and then from LfFe to Lf (SI2). 
 
Discussion 
The present study of the FRET signals obtained when functionalizing lactoferrin 
with two distinct fluorophores, AF430 and AF350, provides not only novel 
molecular information on the iron-loading state of the protein but also on the 
mechanisms underlying these iron loading/unloading processes. Furthermore, the 
results illustrate how this methodology can be useful when performing in vivo 
and in vitro experiments involving Lf iron release or loading. 
Our data show that both the change in the number of fluorophores that can be 
bound to lactoferrin and the variations in their FRET patterns as a function of the 
iron loading level of the protein are strongly dependent on the protein 
conformation. This means that the FRET responses can be used to analyze the 
iron-dependent conformational change of lactoferrin when it converts from its 
apo form to its holo (diferric) form, and can shed light on previously unanswered 










Fig. 8 FRET fluorescence emission spectra for LfFe2-AFs before (left) and after 
(right) incubation with B. breve for 6 h 
 
More precisely, the FRET responses can be used to probe how, following the 
uptake of the first iron(III) ion, the other lobe of the protein is prompted to bind 
the second ion. To the best of our knowledge, none of the information currently 
available provides a definitive answer to this question. 
The results of our computational study, based on an SAS analysis of the Lys 
residues in Lf and LfFe2, clearly indicate that Lys301 is the only residue that is 
able to selectively bind AF430 in Lf (but not in LFe2). This result is supported by 
those obtained from simulated protein–ligand dockings that explicitly modeled 
the binding of the fluorophore to the selected amino acid and showed that AF430 
can easily access a catalytically consistent orientation for binding at Lys301 in Lf 
but not in LfFe nor LfFe2 (Fig. 5). Since Lys301 is located at the iron-binding site 
of the N-lobe and is located at the interface between the N1 and N2 subdomains, it 
appears that some type of conformational change occurs in this domain as a 
consequence of the binding of the first iron to the protein. Additional calculations 
on the available X-ray structures also allowed us to demonstrate that the 
differences in the FRET patterns obtained for Lf, LfFe, and LfFe2 are likely to be 
related to the fluorophores attached to the Lys residues located at the N2 lobe. 
This suggests that the transition between Lf and LfFe2 is likely to involve a major 
contribution from an interdomain change in the N-lobe. 





has been reported to occur at the C-site, at which point the N-site becomes 
capable of acquiring a second iron(III) ion [33]. However, the mechanism by 
which the N-lobe is activated once this first iron(III) ion has been bound to the C-
lobe is not well known and the source of debate. To date, it is believed that the 
binding of the first iron(III) is followed by a series of proton dissociations that 
probably trigger changes in the conformation of the protein, thereby affecting 
the N-site and allowing the capture of the second iron(III) [18]. 
On the one hand, our results suggest that the capture of the first iron(III) ion 
triggers a partial but significant enough interdomain change at the N-lobe. 
Lys301, which is located at the interface between the N1 and N2 subdomains, 
binds an AF430 in Lf but not in LfFe2. The steric hindrance of Lys301 is associated 
to a certain degree with the closing motion that takes place between the N1 and 
N2 subdomains upon the shift from the Lf to the LfFe form of the protein, as 
shown by further SAS analysis. 
Therefore, our results show that the binding of the first metal to Lf involves a 
reorganization of the N2 domain with respect to the N1 one. However, the FRET 
efficiency remains almost unaffected (50 vs 41 %) by the Lf to LfFe transition, 
leading us to suspect that the conformational change is relatively limited. 
The capture of the second iron(III) by the N-lobe results in a significant 
conformational change of the protein as a whole. A drastic increase in FRET is 
observed upon transitioning from LfFe (41%) to LfFe2 (91%). This suggests that a 
marked change in the N2/N1 interface occurs with the binding of the second 
iron. In the absence of an X-ray structure for human LfFe, the results of our joint 
computational–experimental study suggest that the structure of LfFe presents an 
intermediate conformation of the N-lobe that is mainly characterized by 
intersubdomain reorganization. This observation is consistent with the recently 
released structure of an intermediate conformation of di-iron and di-bismuth 
human transferrin, where the main structural changes were observed at the N2 
domain and at the interface between both subdomains [34]. Our interpretations 
are also consistent with those of other authors, who have envisaged the possibility 
that cooperativity between the C- and N-lobes occurs via dynamic event 





In addition to the novel information obtained on the molecular mechanism of iron 
loading by lactoferrin, the present study illustrates how the FRET profile of 
lactoferrin can be used as a tool to monitor some specific processes of iron 
metabolism in which this protein plays a relevant role. In particular, lactoferrin 
may support the growth of some nonpathological but beneficial bacteria [14, 15]. 
Indeed, lactoferrin coexists with several lactic acid bacteria, such as 
Bifidobacterium and Lactobacilli, in breast milk. These Gram-positive anaerobic 
bacteria proliferate in the human intestinal tract and are classified as probiotic 
bacteria because of their health benefits [35–37]. Our results confirm that, as for 
other healthy bacteria, human iron-saturated lactoferrin acts as an iron donor for 
B. breve. The evolution of the FRET pattern of the supernatant solution after the 
incubation of LfFe2 with the bacteria (Fig. 8) points to complete iron transfer from 
LfFe2 to the bacteria. Moreover, the fact that the protein concentration in the 
extrabacterial medium does not significantly change suggests that lactoferrin does 
not require protein internalization and that, unlike other transferrins, it is not 
involved in Fe(III) transport by receptor-mediated endocytosis. This kind of iron 
trafficking has only been observed in certain Gram-negative bacteria [38]. 
 
Conclusions 
Fluorescent lactoferrins with different iron loading levels were prepared by 
labeling the proteins with the Alexa Fluor dyes AF350 and AF430. All of the 
fluorescent lactoferrin samples showed FRET, but interestingly with distinctive 
patterns. This indicates that energy transfer from the donor to the acceptor 
fluorophore varies with the iron loading level of lactoferrin. Since the iron loading 
level of lactoferrin determines its tertiary structure, the FRET pattern of the 
sample correlates with its iron content. Moreover, the results of our joint 
experimental-computational study provide an additional piece of evidence relating 
to the subdomain dynamics of the N-lobe upon iron binding. They are consistent 
with a cooperative transfer mechanism between the C- and N-lobes of lactoferrin 
that involves interdomain conformational changes during the transition from the 
Lf to the LfFe form, although the closed conformation found in LfFe2 is not 





In a further achievement, we used this FRET to iron level correlation for 
lactoferrin as a tool to monitor the interaction between human lactoferrin and 
Bifidobacteria. Specifically, we used this methodology to demonstrate that 
lactoferrin supplies iron to these healthy bacteria and, furthermore, that this 
process takes place without iron(III) trafficking by receptor mediated endocytosis. 
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